ImmunityBio Class Action Lead Plaintiff Deadline Approaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: Newsfilter
- Lawsuit Deadline: Investors must file a motion by May 26, 2026, to be appointed as lead plaintiff in the ImmunityBio, Inc. (NASDAQ:IBRX) class action, making this date crucial for shareholders wishing to participate in the litigation.
- Stock Price Impact: Following the FDA's determination that the company's promotional communications were false or misleading, IBRX shares fell by 21%, translating to a $1.98 loss per share, which significantly undermines investor confidence and the company's reputation.
- Lead Plaintiff Role: The lead plaintiff oversees litigation strategy, and while not all investors need to be lead plaintiffs to recover losses, all shareholders who purchased IBRX stock during the class period and suffered losses are eligible for compensation.
- Absent Shareholder Rights: Investors who do not apply for lead plaintiff status remain
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.050
Low
5.00
Averages
7.33
High
9.00
Current: 8.050
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Bladder Cancer Therapy Application Accepted by FDA
- FDA Application Acceptance: ImmunityBio's marketing application for its bladder cancer therapy Anktiva has been accepted by the FDA, marking a significant advancement in the company's efforts to expand its product label, which is expected to enhance its market competitiveness.
- Target Action Date: The FDA has set January 6, 2027, as the target action date for this application, providing the company with a clear market timeline that could bolster investor confidence.
- Patient Population Size: Approximately 80% of bladder cancer cases diagnosed annually in the U.S. are non-muscle-invasive bladder cancer (NMIBC), with about 85% of those patients having papillary disease, indicating a substantial potential market for this therapy.
- Clinical Trial Results: The sBLA is supported by data from the QUILT 3.032 Phase 2/3 trial, which showed a 12-month disease-free survival rate of approximately 58% for patients with papillary-only NMIBC, providing strong backing for the FDA's acceptance.
See More
ImmunityBio Seeks ANKTIVA Label Expansion for NMIBC
- FDA Review Progress: The U.S. FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aiming to expand its indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), with a decision expected by January 6, 2027, which could significantly increase treatment options.
- Clinical Data Support: The sBLA submission is based on data from the QUILT-3.032 trial, showing a 12-month disease-free survival rate of 58.2% in 80 high-risk patients treated with ANKTIVA plus BCG, providing scientific justification for the indication expansion that may improve patient outcomes.
- Expert Consensus Reinforcement: At the FDA workshop in May 2026, experts unanimously agreed that CIS and papillary disease are biologically the same, supporting the inclusion of papillary disease in existing treatment protocols, highlighting the urgent treatment needs for BCG-unresponsive patients and furthering the sBLA review.
- Significant Market Potential: The expanded indication for ANKTIVA positions it as a crucial immunotherapy option for BCG-unresponsive patients, likely enhancing ImmunityBio's competitiveness in the bladder cancer treatment market and addressing the urgent needs of approximately 64,000 NMIBC patients diagnosed annually.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, specifically targeting investors who purchased or acquired the company's securities between January 19, 2026, and March 24, 2026, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding their investments.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action filed against ImmunityBio is May 26, 2026, urging investors to act promptly to protect their rights.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company focused on immunotherapy, currently facing legal challenges that may impact shareholder returns and market confidence.
See More
ImmunityBio Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in significant misrepresentations regarding the company's business, operations, and prospects, which could lead to substantial losses for investors.
- Investor Action Deadline: Affected investors must apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery, indicating the urgency of legal proceedings and active participation from investors.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, enhancing investor confidence in participating in the lawsuit and demonstrating the firm's commitment to protecting investor rights.
See More
ImmunityBio's Bladder Cancer Treatment May Soon Gain Approval
- FDA Review Progress: ImmunityBio announced that its supplemental biologics license application (BLA) has been accepted for review by the FDA, which, if approved, will significantly expand the indications for its Anktiva drug and is expected to drive continued sales growth for the company.
- Market Potential Expansion: Currently, approximately 85% of the 64,000 patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in the U.S. each year present with papillary disease, and FDA approval would greatly enlarge Anktiva's target market, enhancing the company's competitiveness in the biopharmaceutical sector.
- Strong Stock Performance: ImmunityBio's stock has quadrupled this year, currently trading at 58 times sales, indicating high market expectations for its future potential, but also suggesting that investors should be cautious and avoid making large investments all at once.
- Rich Clinical Pipeline: In addition to bladder cancer treatments, ImmunityBio is conducting multiple clinical trials across various fields, including lung cancer, ovarian cancer, and HIV, showcasing its broad positioning in the biotechnology sector and potential for future growth.
See More
ImmunityBio's FDA Application Acceptance Boosts Shares by 9%
- FDA Application Approval: ImmunityBio announced that its supplemental biologics license application has been accepted for FDA review, potentially leading to a label expansion for its core treatment Anktiva, resulting in a 9% stock price increase, reflecting market optimism about its future potential.
- Market Expansion Opportunity: The new application expands Anktiva's indications to treat BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease, which could significantly increase the target market, as approximately 85% of the 64,000 NMIBC patients diagnosed annually present with papillary disease.
- Insurance Coverage Outlook: FDA approval would prompt insurers to cover the treatment costs for Anktiva, further enhancing market acceptance and strengthening ImmunityBio's competitive position in the biopharmaceutical sector.
- Future Development Plans: ImmunityBio's clinical trial pipeline spans various diseases, including lung and ovarian cancer; although the stock has quadrupled, investors should remain cautious and consider phased investments to capitalize on future growth potential.
See More
ImmunityBio's Bladder Cancer Therapy Application Accepted by FDA
- FDA Application Acceptance: ImmunityBio's marketing application for its bladder cancer therapy Anktiva has been accepted by the FDA, marking a significant advancement in the company's efforts to expand its product label, which is expected to enhance its market competitiveness.
- Target Action Date: The FDA has set January 6, 2027, as the target action date for this application, providing the company with a clear market timeline that could bolster investor confidence.
- Patient Population Size: Approximately 80% of bladder cancer cases diagnosed annually in the U.S. are non-muscle-invasive bladder cancer (NMIBC), with about 85% of those patients having papillary disease, indicating a substantial potential market for this therapy.
- Clinical Trial Results: The sBLA is supported by data from the QUILT 3.032 Phase 2/3 trial, which showed a 12-month disease-free survival rate of approximately 58% for patients with papillary-only NMIBC, providing strong backing for the FDA's acceptance.
See More
ImmunityBio Seeks ANKTIVA Label Expansion for NMIBC
- FDA Review Progress: The U.S. FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA, aiming to expand its indication to include patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), with a decision expected by January 6, 2027, which could significantly increase treatment options.
- Clinical Data Support: The sBLA submission is based on data from the QUILT-3.032 trial, showing a 12-month disease-free survival rate of 58.2% in 80 high-risk patients treated with ANKTIVA plus BCG, providing scientific justification for the indication expansion that may improve patient outcomes.
- Expert Consensus Reinforcement: At the FDA workshop in May 2026, experts unanimously agreed that CIS and papillary disease are biologically the same, supporting the inclusion of papillary disease in existing treatment protocols, highlighting the urgent treatment needs for BCG-unresponsive patients and furthering the sBLA review.
- Significant Market Potential: The expanded indication for ANKTIVA positions it as a crucial immunotherapy option for BCG-unresponsive patients, likely enhancing ImmunityBio's competitiveness in the bladder cancer treatment market and addressing the urgent needs of approximately 64,000 NMIBC patients diagnosed annually.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, specifically targeting investors who purchased or acquired the company's securities between January 19, 2026, and March 24, 2026, aiming to provide legal support for affected investors.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options regarding their investments.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action filed against ImmunityBio is May 26, 2026, urging investors to act promptly to protect their rights.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is a biotechnology company focused on immunotherapy, currently facing legal challenges that may impact shareholder returns and market confidence.
See More
ImmunityBio Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in significant misrepresentations regarding the company's business, operations, and prospects, which could lead to substantial losses for investors.
- Investor Action Deadline: Affected investors must apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery, indicating the urgency of legal proceedings and active participation from investors.
- No-Cost Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, charging only if they successfully recover funds, enhancing investor confidence in participating in the lawsuit and demonstrating the firm's commitment to protecting investor rights.
See More
ImmunityBio's Bladder Cancer Treatment May Soon Gain Approval
- FDA Review Progress: ImmunityBio announced that its supplemental biologics license application (BLA) has been accepted for review by the FDA, which, if approved, will significantly expand the indications for its Anktiva drug and is expected to drive continued sales growth for the company.
- Market Potential Expansion: Currently, approximately 85% of the 64,000 patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in the U.S. each year present with papillary disease, and FDA approval would greatly enlarge Anktiva's target market, enhancing the company's competitiveness in the biopharmaceutical sector.
- Strong Stock Performance: ImmunityBio's stock has quadrupled this year, currently trading at 58 times sales, indicating high market expectations for its future potential, but also suggesting that investors should be cautious and avoid making large investments all at once.
- Rich Clinical Pipeline: In addition to bladder cancer treatments, ImmunityBio is conducting multiple clinical trials across various fields, including lung cancer, ovarian cancer, and HIV, showcasing its broad positioning in the biotechnology sector and potential for future growth.
See More
ImmunityBio's FDA Application Acceptance Boosts Shares by 9%
- FDA Application Approval: ImmunityBio announced that its supplemental biologics license application has been accepted for FDA review, potentially leading to a label expansion for its core treatment Anktiva, resulting in a 9% stock price increase, reflecting market optimism about its future potential.
- Market Expansion Opportunity: The new application expands Anktiva's indications to treat BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease, which could significantly increase the target market, as approximately 85% of the 64,000 NMIBC patients diagnosed annually present with papillary disease.
- Insurance Coverage Outlook: FDA approval would prompt insurers to cover the treatment costs for Anktiva, further enhancing market acceptance and strengthening ImmunityBio's competitive position in the biopharmaceutical sector.
- Future Development Plans: ImmunityBio's clinical trial pipeline spans various diseases, including lung and ovarian cancer; although the stock has quadrupled, investors should remain cautious and consider phased investments to capitalize on future growth potential.
See More
